Embleema

Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs. Connecting patients directly to medical research and incentivizing them to share their data with tokens, blockchain is the decentralized technology everyone was waiting for to move away from the current linear process of drug approvals, to a new iterative model where trustworthy digital health data is shared in real time between patients, life sciences and regulators. The 21st Century Cures Act (2016) gave the FDA a mandate to accelerate approvals if more patient real world data was shared proactively by pharma. Embleema’s blockchain speeds up this process with patient buy-in, accelerating time to market new drugs.